Advertisement

Multiple Myeloma Medications

Here's a list of the approved drugs to treat multiple myeloma. Click on any of the medications for more info on indications, dosing and side effects.


Quick Filter

*generic version available

E experimental

DRUG Chemotherapy
GENERIC NAME Multiple
DRUG INDICATION

Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, click here.

DRUG Farydak
GENERIC NAME panobinostat
DRUG INDICATION

Farydak is an HDAC inhibitor approved for multiple myeloma, in combination with dexamethasone and Velcade (bortezomib).

DRUG Xpovio
GENERIC NAME selinexor
DRUG INDICATION

Xpovio is the first approved nuclear export inhibitor. It is indicated for the treatment of people with relapsed or refractory (nonresponsive) multiple myeloma or diffuse large B-cell lymphoma.

DRUG Pomalyst
GENERIC NAME pomalidomide
DRUG INDICATION

Pomalyst is an immunomodulator approved for multiple myeloma and Kaposi sarcoma.

DRUG Revlimid
GENERIC NAME lenalidomide
DRUG INDICATION

Revlimid is an immunomodulator approved for multiple myeloma in combination with dexamethasone, for follicular lymphoma and marginal zone lymphomain in combination with Rituxan (rituximab),

and as a single drug for myelodysplastic syndromes and mantle cell lymphoma.

DRUG Thalomid
GENERIC NAME thalidomide
DRUG INDICATION

Thalomid is an immunomodulator approved for multiple myeloma, in combination with dexamethasone.

DRUG Blenrep
GENERIC NAME belantamab mafodotin
DRUG INDICATION

Blenrep is a BCMA-directed antibody-drug conjugate approved for people with heavily pretreated relapsed or refractory multiple myeloma.

DRUG Darzalex, Darzalex Faspro
GENERIC NAME daratumumab
DRUG INDICATION

Darzalex is a CD38 inhibitor approved for newly diagnosed or previously multiple myeloma, in combination with various other medications. Darzalex Faspro is a newer formulation that can be given by subcutaneous injection rather than IV infusion.

DRUG Empliciti
GENERIC NAME elotuzumab
DRUG INDICATION

Empliciti is a SLAMF7 inhibtor approved multiple myeloma, in combination with dexamethasone and Revlimid (lenalidomide).

DRUG Kyprolis
GENERIC NAME carfilzomib
DRUG INDICATION

Kyprolis is a proteasome inhibitor approved for relapsed or refractory multiple myeloma, used alone or in combination with other medications.

DRUG Ninlaro
GENERIC NAME ixazomib
DRUG INDICATION

Ninlaro is a proteasome inhibitor approved multiple myeloma, in combination with dexamethasone and Revlimid (lenalidomide).

DRUG Sarclisa
GENERIC NAME isatuximab-irfc
DRUG INDICATION

Sarclisa is a CD38 inhibitor approved for combination treatment of multiple myeloma in previously treated people.

DRUG Velcade
GENERIC NAME bortezomib
DRUG INDICATION

Velcade is a proteasome inhibitor approved for multiple myeloma and mantle cell lymphoma.


Advertisement